Form 10-Q · Quarterly report
Becton Dickinson 10-Q, filed Aug 6, 2026
- Filed
- CIK
- 0000010795
- Accession no.
- 0000010795-26-000035
Summary
Becton Dickinson reported fiscal third-quarter 2026 revenue of $4.98 billion, up 5.4% from $4.73 billion a year earlier, with growth across all four segments led by BioPharma Systems (+6.6%) and Interventional (+6.4%). Segment income was $617 million for Medical Essentials, $565 million for Interventional, $395 million for Connected Care, and $259 million for BioPharma Systems, with the company citing tariffs, higher labor costs, and costs tied to the El Paso Warning Letter as margin pressures and unfavorable market dynamics in China including volume-based procurement as a drag.
Key points
- Total third-quarter fiscal 2026 revenue rose 5.4% to $4,983 million; U.S. revenue rose 6.9% to $3,081 million and international revenue rose 3.2% to $1,902 million.
- Medical Essentials revenue was $1,675 million (+4.5%) and Connected Care revenue was $1,224 million (+4.9%), with growth in infusion-set utilization and the BD Vacutainer portfolio partly attributed to share gains and competitors' backorders.
- BioPharma Systems revenue rose 6.6% to $670 million on double-digit growth of prefillable solutions for biologic drugs, led by GLP-1 delivery products, partly offset by lower vaccine demand.
- Interventional revenue rose 6.4% to $1,414 million on oncology and Rotarex Atherectomy sales, double-digit PureWick growth, and infection-prevention and tissue-regeneration products.
Written by an AI model from the filing text. It can be incomplete or wrong; the filing on SEC.gov is the record.
From the filing
Item 2. Management’s Discussion Results of Operations Medical Essentials Segment The following summarizes third quarter Medical Essentials revenues by organizational unit: Three months ended June 30, (Millions of dollars) 2026 2025 Total Change Estimated FX Impact FXN Change Medication Delivery Solutions $ 1,164 $ 1,132 2.8 % 1.2 % 1.6 % Specimen Management 511 470 8.7 % 1.7 % 7.0 % Total Medical Essentials Revenues $ 1,675 $ 1,602 4.5 % 1.3 % 3.2 % The Medical Essentials segment’s revenue growth in the third quarter of 2026 primarily reflected the following: •Strong U.S. …
An excerpt of the text as filed with the SEC, cut for length.
Readster writes AI-generated summaries of public filings for research purposes only. Summaries can be incomplete or wrong — check the original filing on SEC.gov before relying on it. Nothing here is investment, legal or medical advice.